Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus

References

• Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology. 2006;45(11):1370–1375.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wilkinson S, Riaz M, et al. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol. 2012;30(6):962–971.
   PubMedGoogle Scholar
• Groff GD, Shenberger KN, Wilke WS, et al. Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum. 1983;12:333–347.
   PubMed Web of Science ®Google Scholar
• Steinsson K, Weinstein A, Korn J, et al. Low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1982;9(6):860–866.
   PubMedGoogle Scholar
• Furst DE, Erikson N, Clute L, et al. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol. 1990;17(12):1628–1635.
   PubMedGoogle Scholar
• Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991;90(1):295–298.
   PubMedGoogle Scholar
• Jeurissen ME, Boerbooms AM, Van De Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum. 1991;34(8):961–972.
   PubMedGoogle Scholar
• Sany J, Anaya JM, Lussiez V, et al. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J Rheumatol. 1991;18(9):1323–1327.
   PubMedGoogle Scholar
• Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol. 1989;28(2):147–153.
   PubMedGoogle Scholar
• Zanto E. Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety. Clin Rheumatol. 1989;8(3):323.
   PubMedGoogle Scholar
• Schnabel A, Burchardi C, Gross W. Major infection during methotrexate treatment for rheumatoid arthritis. Semin Arthritis Rheum. 1996;25(5):357–359.
   PubMedGoogle Scholar
• Van Der Veen MJ, Van Der Heide A, Kruize AA, et al. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994;53(4):224–228.
   PubMed Web of Science ®Google Scholar
• Veetil B, Myasoedova E, Matteson E, et al. Incidence and time trends of Herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2013;65(6):854–861.
   PubMedGoogle Scholar
• Qian J, Lassere MN, Heywood AE, et al. Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults. Rheumatology (Oxford). 2021;60(11):5042–5051.
   PubMedGoogle Scholar
• Smitten A, Choi H, Hochberg M, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheumat. 2007;57(8)1431–1438.
   PubMed Web of Science ®Google Scholar
• McDonald J, Zeringue A, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(1):364–1371.
   Google Scholar
• Strangfeld A, Listing JD, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti–TNF-a agents. JAMA. 2009;301(7):737–744.
   PubMed Web of Science ®Google Scholar
• García-Doval I, Pérez-Zafrilla B, Descalzo M, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69(10):1751–1755.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of Adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–229.
   PubMed Web of Science ®Google Scholar
• Sakai R, Komano J, Tanaka M, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res. 2012;64:1125–1134.
   PubMed Web of Science ®Google Scholar
• Serac G, Tubach F, Mariette X, et al. Risk of Herpes Zoster in Patients Receiving Anti-TNF-a in the Prospective French RATIO Registry. J Inv Dermat. 2012;132(3):726–729.
   PubMedGoogle Scholar
• Galloway J, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229–234.
   PubMed Web of Science ®Google Scholar
• Widdifield J, Bernatsky S, Paterson M, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):353–361.
   PubMed Web of Science ®Google Scholar
• Winthrop K, Baddley J, Chen L, et al. Association between the initiation of anti-TNF therapy and the risk of herpes zoster. JAMA. 2013;309(9):887–895.
   PubMed Web of Science ®Google Scholar
• Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. JEADV. 2014;28(7):846–852.
   Google Scholar
• Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(3):215–221.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Reed D, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010;69(2):380–386.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Viala C, Nam J, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529–535.
   PubMed Web of Science ®Google Scholar
• Desai R, Thaler KJ, Mahlknecht P, et al. Comparative risk of harm associated with the use of targeted immunomodulators- A systematic review. Arthritis Care Res. 2016;68(8):1078–1088.
   Web of Science ®Google Scholar
• Segan J, Staples MP, March L, et al. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors. Intern Med J. 2015;45(3):310–318.
   PubMedGoogle Scholar
• Torii H, Terui T, Matsukawa M, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2015;42(1):1–12.
   PubMedGoogle Scholar
• Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015;67(5):731–736.
   PubMed Web of Science ®Google Scholar
• Zisman D, Bitterman H, Shalom G, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016;75(1):131–135.
   PubMedGoogle Scholar
• Lee E, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• Winthrop K, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthr Rheum. 2014;66(10):2675–2684.
   PubMed Web of Science ®Google Scholar
• Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol. 2016;43(8):869–880.
   PubMed Web of Science ®Google Scholar
• Jeong S, Choi S, Park SM, et al. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Arthritis Res Ther. 2022;24(1):180.
   PubMedGoogle Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(10):1755–1766.
   PubMed Web of Science ®Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80(3):304–311.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose- finding study (DARWIN 2). Ann Rheum Dis. 2017;76(6):1009–1019.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose- finding study (DARWIN 1). Ann Rheum Dis. 2017;76(6):998–1008.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315–325.
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to Adalimumab in patients with active rheumatoid arthritis. Z Rheumatol. 2020;79(8):785–796.
   PubMedGoogle Scholar
• Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendation for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
   PubMed Web of Science ®Google Scholar
• Katz J, McDermott MP, Cooper EM, et al. Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain. 2005;6(12):782–790.
   PubMedGoogle Scholar
• Wu PH, Chuang YS, Lin YT. Does herpes zoster increase the risk of stroke and myocardial? Comprehensive review. J Clin Med. 2019;8(4):547.
   PubMedGoogle Scholar
• Yang Q, George MG, Chang A, et al. Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke. Neurology. 2020;95(6):708–717.
   Google Scholar
• Klaric JS, Beltran TA, McClenathan BM. An association between herpes zoster vaccination and stroke reduction among elderly individuals. Mil Med. 2019;184(Supplement_1):126–132.
   PubMedGoogle Scholar